China’s Luye Pharma Taps Initial Share Sale Opportunity In Hong Kong
This article was originally published in PharmAsia News
Luye left the Singapore Stock Exchange in 2012 when the majority of its shares were owned by a South Korean firm. But now Hong Kong beckons – with Luye just one of several China pharma companies looking to tap a revived IPO market closer to home with trading in the shares set to begin on the Hong Kong exchange July 9.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.